We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+0.28%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.95B
AUM Growth
-$468M
Cap. Flow
-$179M
Cap. Flow %
-6.06%
Top 10 Hldgs %
70.08%
Holding
59
New
4
Increased
11
Reduced
13
Closed
6

Top Buys

Rank Stock Value
1
SEPN
Septerna Inc
SEPN
+$58M
2
RVMD icon
Revolution Medicines
RVMD
+$35.5M
3
VERV
Verve Therapeutics
VERV
+$35.3M
4
XNCR icon
Xencor
XNCR
+$33.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$31.5M

Top Sells

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$102M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$58.2M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$44.7M
4
CGON icon
CG Oncology
CGON
+$37.5M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$37M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
1
MoonLake Immunotherapeutics
MLTX
$1.59B
$1.07B 36.25%
19,751,284
-2,000,000
-9% -$102M
KYMR icon
2
Kymera Therapeutics
KYMR
$8.72B
$208M 7.04%
5,161,801
– –
RVMD icon
3
Revolution Medicines
RVMD
$40.3B
$183M 6.2%
4,181,179
+702,567
+20% +$35.5M
AXSM icon
4
Axsome Therapeutics
AXSM
$11.7B
$117M 3.98%
1,388,064
+342,064
+33% +$31.5M
MIRM icon
5
Mirum Pharmaceuticals
MIRM
$6.73B
$116M 3.92%
2,796,513
-279,394
-9% -$11.6M
XOMA
6
DELISTED
Xoma
XOMA
$95.5M 3.24%
3,633,743
– –
PTGX icon
7
Protagonist Therapeutics
PTGX
$8.75B
$73.3M 2.49%
1,900,015
+49,848
+3% +$2.17M
GHRS icon
8
GH Research
GHRS
$1.97B
$72.8M 2.47%
10,400,158
– –
CGEM icon
9
Cullinan Oncology
CGEM
$1.06B
$70M 2.37%
5,750,683
– –
ZYME icon
10
Zymeworks
ZYME
$1.66B
$63.1M 2.14%
4,308,935
-299,000
-6% -$4.18M
SEPN
11
Septerna Inc
SEPN
$1.54B
$56.2M 1.9%
+2,452,024
New +$58M
TYRA icon
12
Tyra Biosciences
TYRA
$1.95B
$54.8M 1.86%
3,944,194
-717,000
-15% -$13M
ACIU icon
13
AC Immune
ACIU
$233M
$52.7M 1.79%
19,522,436
– –
XNCR icon
14
Xencor
XNCR
$1.56B
$52.6M 1.78%
2,288,760
+1,438,760
+169% +$33.1M
GPCR icon
15
Structure Therapeutics
GPCR
$3.46B
$48M 1.63%
1,771,417
-467,569
-21% -$16.6M
CELC icon
16
Celcuity
CELC
$4.31B
$45.4M 1.54%
3,466,000
– –
LKFT
17
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$43.2M 1.46%
1,569,422
– –
VERV
18
DELISTED
Verve Therapeutics
VERV
$38.9M 1.32%
6,904,050
+6,254,050
+962% +$35.3M
ANNX icon
19
Annexon
ANNX
$857M
$35.9M 1.22%
7,000,000
– –
AGIO icon
20
Agios Pharmaceuticals
AGIO
$1.93B
$35.3M 1.2%
1,073,755
-116,352
-10% -$5.47M
ETNB
21
DELISTED
89bio
ETNB
$33.9M 1.15%
4,333,885
-2,477,746
-36% -$20.4M
OLMA icon
22
Olema Pharmaceuticals
OLMA
$1.03B
$33.3M 1.13%
5,715,893
-3,420,000
-37% -$34.2M
CDTX
23
DELISTED
Cidara Therapeutics
CDTX
$29.4M 1%
1,092,796
+389,731
+55% +$6.33M
ELDN icon
24
Eledon Pharmaceuticals
ELDN
$261M
$25.9M 0.88%
6,293,282
– –
FHTX icon
25
Foghorn Therapeutics
FHTX
$274M
$25M 0.85%
5,302,000
– –
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2024 Portfolio in Review

As of Q4 2024, BVF Inc held 59 positions worth $2.95B, down 14% from $3.42B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

BVF Inc withdrew a net $179M in Q4 2024, closing 6 positions and reducing 13 holdings. Its most notable exit was Ionis Pharmaceuticals, an estimated $58.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, BVF Inc opened a new position in Septerna Inc worth $56.2M.

  • BVF Inc's largest Q4 2024 buy was Septerna Inc: 2,452,024 shares worth $56.2M.
  • BVF Inc added most to Revolution Medicines in Q4 2024, an estimated $35.5M increase.
  • BVF Inc's biggest Q4 2024 reduction was MoonLake Immunotherapeutics, cutting an estimated $102M.
  • BVF Inc fully exited Ionis Pharmaceuticals in Q4 2024, selling an estimated $58.2M.
  • BVF Inc's ten largest holdings make up 70% of its $2.95B portfolio in Q4 2024.
  • BVF Inc opened 4 new positions and closed 6 in Q4 2024.
  • BVF Inc's portfolio value fell 14% quarter-over-quarter to $2.95B.

Based on BVF Inc's 13F filing for Q4 2024, filed 14 Feb 2025.